ClinicalTrials.gov
public full text
Public Domain
Safety Evaluation of 3K3A-APC in Ischemic Stroke
The purpose of this study was to evaluate the safety, pharmacokinetics (PK) and preliminary efficacy of multiple ascending intravenous doses of 3K3A-APC, a Recombinant Variant of Human activated protein C (APC), in in the treatment of acute ischemic stroke following treatment with recombinant tissue plasminogen activator (tPA), mechanical thrombectomy or both.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Butyphthalide in Combination With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke#1124499
- Prospective Record Of the Use of Dabigatran in Patients With Acute Stroke or TIA#902634
- Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of Care#873495
- Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke.#812499
- The Screening of Neuroprotective Biomarkers After Acute Ischemic Stroke#806349
Record · ID 1100809
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive